Randomised, controlled, open-label pragmatic trial evaluating changes in functional exercise capacity after primary care PUlmonary REhabilitation in patients with long COVID: protocol of the PuRe-COVID trial in Belgium

• Published in: BMJ open 2023-06, Vol.13 (6), p.e071098-e071098
• Main Authors: Volckaerts, Tess, Vissers, Dirk, Burtin, Chris, Van Meerbeeck, Xavier, de Soomer, Kevin, Oostveen, Ellie, Claes, Kim, Roelant, Ella, Verhaegen, Iris, Thomeer, Michiel, Criel, Maarten, Quadflieg, Kirsten, Cops, Dries, Ruttens, David, Lapperre, Thérèse S
• Format: Article
• Language: English
• Subjects: Clinical trials; COVID-19; Exercise; Long COVID; Maximum oxygen consumption; medical education & training; Physical fitness; Physical therapy; primary care; Recovery (Medical); Rehabilitation; Rehabilitation Medicine
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-071098

IntroductionLong COVID is a prevalent condition with many multisystemic symptoms, such as fatigue, dyspnoea, muscle weakness, anxiety, depression and sleep difficulties, impacting daily life and (social and physical) functioning. Pulmonary rehabilitation (PR) may improve physical status and symptoms of patients with long COVID, yet the evidence is limited. Therefore, this trial aims to study the effect of primary care PR on exercise capacity, symptoms, physical activity and sleep in patients with long COVID.Methods and analysisPuRe-COVID is a prospective, pragmatic, open-label, randomised controlled trial. A sample of 134 adult patients with long COVID will be randomised to a 12 week PR programme in primary care, supervised by a physiotherapist or to a control group, following no PR. A 3 month and 6 month follow-up period is foreseen. The primary endpoint will be the change in exercise capacity measured by 6-minute walk distance (6MWD) at 12 weeks, hypothesising a more significant improvement in the PR group. Other parameters, such as pulmonary function tests (including maximal inspiratory pressure/maximal expiratory pressure), patient-reported outcomes (COPD Assessment Test, modified Medical Research Council Dyspnoea Scale, Checklist Individual Strength, post-COVID-19 Functional Status, Nijmegen questionnaire, Hospital Anxiety and Depression Scale, Work Productivity and Activity Impairment Questionnaire and EuroQol-5D-5L), physical activity measured by an activity tracker, hand grip strength and sleep efficiency, are secondary and exploratory outcomes.The recruitment started on 19 April 2022, and 52 patients were included as of 14 December 2022.Ethics and disseminationEthical approval was obtained in Belgium from the relevant institutional review boards on 21 February 2022 (Antwerp University Hospital, approval number 2022-3067) and on 1 April 2022 (Ziekenhuis Oost-Limburg in Genk, approval number Z-2022-01). Findings from this randomised controlled trial will be disseminated in peer-reviewed publications and presentations at international scientific meetings.Trial registration numberNCT05244044.